Sandbox carlos: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) Created page with " {{PBI|Human herpesvirus 8 (KSHV)}} :* 1. '''Mild to moderate Kaposi sarcoma''' ::* Preferred regimen: initiate or optimize ART :* 2. '''Advanced Kaposi sarcoma (ACTG Stage T..." |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 15: | Line 15: | ||
::* Preferred regimen (2): [[Ganciclovir]] 5 mg/kg IV q12h for 3 weeks | ::* Preferred regimen (2): [[Ganciclovir]] 5 mg/kg IV q12h for 3 weeks | ||
::* Preferred regimen (3): [[Valganciclovir]] 900 mg PO BID {{and}} [[Zidovudine]] 600 mg PO q6h for 7–21 days | ::* Preferred regimen (3): [[Valganciclovir]] 900 mg PO BID {{and}} [[Zidovudine]] 600 mg PO q6h for 7–21 days | ||
::* Alternative regimen: [[Rituximab]] 375 mg/m2 given weekly for 4–8 weeks (may be an alternative to or used adjunctively with antiviral therapy) | |||
Revision as of 18:42, 14 July 2015
- Human herpesvirus 8 (KSHV)
Return to Top
- 1. Mild to moderate Kaposi sarcoma
- Preferred regimen: initiate or optimize ART
- 2. Advanced Kaposi sarcoma (ACTG Stage T1, including disseminated cutaneous or visceral Kaposi sarcoma)
- Preferred regimen: chemotherapy (per oncology consult) AND ART
- 3. Primary effusion lymphoma
- Preferred regimen: chemotherapy (per oncology consult) AND ART
- Note: Valganciclovir PO or Ganciclovir IV can be used as adjunctive therapy.
- 4. Multicentric Castleman's disease
- Preferred regimen (1): Valganciclovir 900 mg PO bid for 3 weeks
- Preferred regimen (2): Ganciclovir 5 mg/kg IV q12h for 3 weeks
- Preferred regimen (3): Valganciclovir 900 mg PO BID AND Zidovudine 600 mg PO q6h for 7–21 days
- Alternative regimen: Rituximab 375 mg/m2 given weekly for 4–8 weeks (may be an alternative to or used adjunctively with antiviral therapy)